Pallade Veneta - Conflicting US rulings leave fate of abortion pill in doubt

Conflicting US rulings leave fate of abortion pill in doubt


Conflicting US rulings leave fate of abortion pill in doubt

Conflicting rulings by two federal judges have left the future of abortion pills in the United States deeply uncertain, likely placing the divisive issue squarely in the lap of the Supreme Court.

Change text size:

A ruling Friday by federal judge Matthew Kacsmaryk in Texas banned the widely used drug mifepristone (RU 486) nationwide, boosting conservatives' efforts to further restrict abortion rights after the Supreme Court last year allowed states to prohibit them.

The unprecedented rejection of a drug approved in 2000 by the US Food and Drug Administration (FDA) -- and found safe by scientific consensus -- sparked outrage on the political left.

Kacsmaryk, in his ruling, adopted language used by abortion opponents, referring to abortion providers as "abortionists" and saying the drug was used to "kill the unborn human."

His ruling brought an immediate vow from the Biden administration and the drug's maker to appeal the matter in federal court.

Attorney General Merrick Garland said the Justice Department would ask the appeals court to stay the ban by Kacsmaryk, an ultraconservative Donald Trump appointee, until the case is finally resolved.

If the Texas ruling holds, it would complicate matters not just in the states now banning or sharply limiting abortions, but also in those where the procedure remains legal.

- Widely used -

Mifepristone has been used as part of a two-drug regimen by 5.6 million women since 2000.

But adding to the uncertainty and increasing the odds the matter ends up before the Supreme Court was a contradictory ruling from a Washington state judge that came just hours after Kacsmaryk's.

District Judge Thomas Rice, a Barack Obama appointee, ruled in a separate case -- brought by several states where abortion is legal -- that mifepristone is "safe and legal" and that the FDA must preserve access to it in more than a dozen states.

For now the drug remains legal, Alexis McGill Johnson, the head of Planned Parenthood, one of the largest pro-abortion groups in the country, said Friday.

Several abortion clinics also said Friday that they would continue using mifepristone until ordered not to by the FDA, US media reported.

Kacsmaryk paused the effect of his ruling for a week, allowing time for the administration and drugmaker Danco Laboratories to file before the US Fifth Circuit Court of Appeals in Louisiana, which hears cases from Texas.

The Justice Department is still reviewing Rice's ruling, Garland said in a statement.

- 'Remains safe' -

Given the sharply conflicting court rulings, the Justice Department might opt to take the case directly to the Supreme Court and not wait for the Fifth Circuit to act.

The high court could decide to take up the case on an emergency basis, which would require making room in an already crowded agenda at the end of the current term.

In that case, the court -- with six conservative justices outnumbering the three liberals -- could hear the case within days, or weeks, but sometime before the current session ends on June 30.

Chief Justice John Roberts, a conservative, is deeply protective of the image of the institution, and he might be expected to vote with the three liberals in favor of mifepristone. The additional vote of one other conservative could provide a majority for the drug.

The court's ruling last June to overturn the longstanding Roe v. Wade decision protecting abortion rights shifted considerable attention to medication abortions.

Most of them involve mifepristone in a two-drug regimen. A patient first takes a mifepristone pill to end the pregnancy, then a day later takes the drug misoprostol to induce contractions that expel the embryo or fetus.

Misoprostol can be used on its own to cause abortions, but the two-step procedure is considered more effective and can be more painful.

More than half of abortions in the US are done with medication.

Kacsmaryk, in his ruling, said the two-drug regimen had resulted in "thousands of adverse events suffered by women and girls," including intense bleeding and psychological trauma.

But the FDA, researchers and the drugmaker say decades of experience have proven the medication to be safe and effective.

Michigan Governor Gretchen Whitmer, a Democrat, tweeted:

"Despite this ruling, I want to be clear: abortion, including medication abortion, remains safe and legal in the state of Michigan."

Women's March, which has been organizing organizing major women's rights demonstrations in recent years, called for a nationwide rally defending abortion rights for April 15.

M.Jacobucci--PV

Featured

Michigan Pizza Driver Halts $785K GoFundme After Viral Prank

Walt Zerod, a Michigan father of four who became the center of a viral online controversy, has paused a crowdfunding campaign that raised nearly $785,000. The Red Baron delivery driver announced on Thursday that he is closing the page to focus on his family during the holiday season.

Kate McClymont Testifies at Alan Jones Trial Over Reporting Methods

Investigative journalist Kate McClymont took the stand in the thirteenth week of the trial against former radio personality Alan Jones, facing rigorous cross-examination over her reporting methodology. Her testimony focused on text message exchanges with police and the verification process that led to the legal proceedings.

Chervon Names Doug Palmer Vice President of Finance - Canada

TORONTO, ON / ACCESS Newswire / November 5, 2026 / Effective November 9, 2026, Chervon names Doug Palmer Vice President of Finance - Canada, reporting to Neil Harrison, Vice President and Managing Director of Chervon Canada. He will also have a dotted-line reporting relationship to Ryan Wang, Chief Financial Officer, Chervon NA.

Polaris Renewable Energy Announces Q3 2026 Results

TORONTO, ON / ACCESS Newswire / November 5, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and nine months ended September 30, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise.

Change text size: